MedTrace Logo

Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq

NCT03344003 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2024-08-09

Study results available
· View outcomes & findings →

Summary

Uncontrolled, multi-centre, non-interventional study with a prospective and a retrospective cohort, to evaluate the efficacy of Wilate or Nuwiq in achieving complete or partial immune tolerance induction (ITI) success in severe and moderate haemophilia A patients with inhibitors

Conditions

Interventions

DRUG

Wilate or Nuwiq

Wilate or Nuwiq administered via intravenous injection

Sponsors & Collaborators

  • Octapharma

    lead INDUSTRY

Principal Investigators

  • Sri Adapa · Octapharma

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-28
Primary Completion
2020-11-20
Completion
2020-11-20

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03344003 on ClinicalTrials.gov